| Company Name: |
Guangzhou PI PI Biotech Inc
|
| Tel: |
+86-020-81716320 +86-13602409664 |
| Email: |
Sales@pipitech.com |
| Products Intro: |
Product Name:Lenalidomide-d5
CAS:1227162-34-6
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com Remarks:3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione-d5; 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-d5; CC-5013-d5
|
| Company Name: |
Artis Biotech Co. Ltd.
|
| Tel: |
19138486554 18582380095 |
| Email: |
sales@artisbio.com |
| Products Intro: |
Product Name:Lenalidomide-d5
CAS:1227162-34-6
Purity:98% HPLC Package:5mg 20mg 50mg 100mg 200mg 1g
|
| Company Name: |
Shenzhen SUNGENING Bio-Medical Co., Ltd.
|
| Tel: |
0755-28967200 13631290199 |
| Email: |
wxf@sungening.com |
| Products Intro: |
Product Name:Lenalidomide D5
CAS:1227162-34-6
Purity:99% HPLC or More Package:10MG;25MG;50MG;100MG
|
- Lenalidomide-D5
-
- $0.00 / 5mg
-
2023-05-27
- CAS:1227162-34-6
- Min. Order: 1mg
- Purity: 96%
- Supply Ability: 50 mg
|
| | Lenalidomide-d5 Basic information |
| Product Name: | Lenalidomide-d5 | | Synonyms: | 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-d5;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione-d5;CC-5013-d5 | | CAS: | 1227162-34-6 | | MF: | C13H8D5N3O3 | | MW: | 264.29142889 | | EINECS: | | | Product Categories: | | | Mol File: | 1227162-34-6.mol |  |
| | Lenalidomide-d5 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: soluble,Methanol: soluble | | form | A solid | | color | White to off-white |
| | Lenalidomide-d5 Usage And Synthesis |
| Biological Activity | Lenalidomide-d5 is intended for use as an internal standard for the quantification of lenalidomide by GC- or LC-MS. Lenalidomide is related to thalidomide and, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.1 It also induces proliferation and enhances the functional capacity of T lymphocytes, amplifying co-stimulatory signaling pathways.2 Lenalidomide is effective in hematologic cancers, including lymphomas and myelomas.3,4 | | References | 1.Kim, K., An, S., Cha, H.J., et al.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cellsOncol.Lett.5(2)588-596(2013)
2.McDaniel, J.M., Pinilla-Ibarz, J., and Epling-Burnette, P.K.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesAdv. Hematol.513702(2012)
3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012)
4.Merli, M., Ferrario, A., Basilico, C., et al.Novel agents in indolent lymphomasTher.Adv.Hematol.4(2)133-148(2013) |
| | Lenalidomide-d5 Preparation Products And Raw materials |
|